Skip to main content

Table 1 Baseline patient characteristics among all three adjuvant NY-ESO-1 clinical trials

From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

 

NCT00821652

NCT01079741

NCT00124124

 
 

N = 22

N = 35

N = 34

 
 

N(%)/Mean(SD)

N(%)/Mean(SD)

N(%)/Mean(SD)

P-Value

Age

59.68 (13.60)

55.49 (15.16)

56.38 (11.82)

0.5134

Sex

   

0.2446

 Female

9 (40.91)

14 (40.00)

20 (58.82)

 

 Male

13 (59.09)

21 (60.00)

14 (41.18)

 

Thicknessa

2.63 (1.64)

2.22 (1.84)

4.48 (5.63)

0.0122

Ulceration

   

0.1916

 Present

7 (31.82)

11 (31.43)

18 (52.94)

 

 Absent

10 (45.45)

17 (48.57)

14 (41.18)

 

 Undetermined

5 (22.73)

7 (20.00)

2 (5.88)

 

AJCC Stage

   

0.0146

 IIB

0 (0.00)

3 (8.57)

7 (20.59)

 

 IIC

1 (4.55)

1 (2.86)

0 (0.00)

 

 IIIA

5 (22.73)

4 (11.43)

6 (17.65)

 

 IIIB

5 (22.73)

11 (31.43)

10 (29.41)

 

 IIIC

4 (18.18)

12 (34.29)

10 (29.41)

 

 IV

7 (31.82)

4 (11.43)

0 (0.00)

 

 Undetermined

0 (0.00)

0 (0.00)

1 (2.94)

 

Histologic Subtype

   

0.5588

 Nodular

6 (27.27)

7 (20.00)

12 (35.29)

 

 Superficial Spreading

4 (18.18)

5 (14.29)

7 (20.59)

 

 Other

3 (13.64)

2 (5.71)

4 (11.76)

 

 Undetermined

9 (40.91)

21 (60.00)

11 (32.35)

 

Primary site

   

0.2624

 Anterior Trunk

0 (0.00)

4 (11.43)

6 (17.65)

 

 Arms

3 (13.64)

5 (14.29)

1 (2.94)

 

 Head/Neck

5 (22.73)

3 (8.57)

6 (17.65)

 

 Legs

8 (36.36)

15 (42.86)

12 (35.29)

 

 Posterior Trunk

3 (13.64)

6 (17.14)

8 (23.53)

 

 Unknown

3 (13.64)

2 (5.71)

1 (2.94)

 
  1. amissing values for thickness: NCT00821652: 4; NCT01079741: 5;NCT00124124: 1